HPV-SEQ enables high-resolution molecular monitoring of patients with HPV-driven cancers.
Several studies are underway using HPV-SEQ to de-escalate HPV-driven cancer treatment to reduce toxicities without compromising survival outcomes. Assessment of quantitative cfHPV-DNA in the convenient biomarker-driven strategy to guide personalized treatment in HPV-positive oropharyngeal cancer (OPC).1
“The ability to reliably detect HPV-DNA in plasma at such low frequency shows HPV-SEQ could be a promising non-invasive biomarker test for effectively assessing treatment response, appropriately de-intensifying treatment using real-time dynamic HPV quantification, and monitoring HPV-positive OPC patients’ post-treatment. Therefore, the HPV-SEQ test has the potential to be an important tool for oncologists in treating patients with HPV-associated head and neck cancer,” he concluded.2
Dr. Nishant Agrawal,
Professor of Surgery at the University of Chicago.
CLIA-validated, ultra-sensitive quantitative blood test for the detection of cell-free HPV 16 and 18 DNA (cfHPV-DNA, this panel detects as few as five HPV 16 and 18 molecules in a background of 20,000 wild-type molecules (0.03% allele frequency).
